RSS Feeds
Potentially Fatal Interaction between Diltiazem and Statins
- Patrick Gladding, MBCHB, BHB;
- Helen Pilmore, MBCHB, FRACP, MD; and
- Colin Edwards, MBBCH(WITS), FCP(SA), FRACP
- From Auckland Healthcare Services Ltd., Grafton, and North Shore Hospital, Takapuna, Auckland, New Zealand.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: The interaction of diltiazem and statins, metabolized through cytochrome P450 3A4, leads to increased risk for rhabdomyolysis.
Objective: To describe the interaction between diltiazem and simvastatin–atorvastatin and highlight its clinical significance.
Case Reports: In case 1, a 59-year-old woman receiving long-term ambulatory peritoneal dialysis because of diabetes-induced renal failure presented with an ischemic toe. …
